Cardiff Oncology Inc (CRDF) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.33 (+2.31%), Market cap $0.11B, 52-week low–high $1.48 ~ $4.45.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizum
Financial statements, price targets, institutional (13F) holdings and related news for Cardiff Oncology Inc are updated in real time on BlackAll Trade.
Cardiff Oncology Inc trades at $1.33 (+2.31%). Real-time quotes and charts are available on BlackAll Trade.
Cardiff Oncology Inc has a market cap of about $0.11B.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and